A CU Anschutz Cancer Center oncologist, Chris Lieu, MD, highlights the promise of the KRAS-targeting drug daraxonrasib as Ben Sasse reports major tumor reduction and extended survival.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045